Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Investor Alert: Deadline in Lawsuit on May 29, 2026

A deadline is coming up on May 29, 2026 in the lawsuit filed for certain investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) over alleged securities laws violations by Aldeyra Therapeutics, Inc.

Investors who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) have certain options and there are strict and short deadlines running. Deadline: May 29, 2026. Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Lexingtonm, MA based Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

On March 17, 2026, Aldeyra issued a press release "announcing receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease." According to Aldeyra's press release, "[t]he CRL stated that there is 'a lack of substantial evidence consisting of adequate and well-controlled investigations ... that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling' and that 'the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.' The letter also stated that the 'inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings' and that the 'totality of evidence from the completed clinical trials does not support the effectiveness of the product.'"

Shares of Aldeyra Therapeutics, Inc. (NASDAQ :ALDX) declined from $7..20 per share on March 12, 2025, to as lowas $1.07 per share on March 17, 2026.

According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges on behalf of purchasers of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) common shares between November 3, 2023 and March 16, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 3, 2023 and March 16, 2026, the defendants made false and/or misleading statements and/or failed to disclose that: the results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent, that the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful, and that as a result, defendants' statements about Aldeyra's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times

Those who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.